Coming December: ASH publishes its late-breaking abstracts. We’ll add the organizations presenting them.

CHU de Lille at ASH 2026

Dec 12–15, 2026 New Orleans, LA ~30k attendees Website

CHU de Lille brings 10 presentations to ASH 2026 in New Orleans. Its program centres on myeloma, acute myeloid leukemia and hypereosinophilic syndrome. It includes comparisons of elranatamab with standard regimens and measurable residual disease testing.

OrganizationASH 2026 Attendance
CHU de Lille
Lille, France
Hospitals & cancer centres
Lille University Hospital, a large public teaching hospital in northern France.
Symposium
Fri Dec 11
7:00am–10:00am
Anti-BCMA Bispecific Antibodies in Multiple Myeloma: From Biology to Real-World Implementation
Bispecific antibodies targeting B-cell maturation antigen in myeloma, from mechanism and resistance to trial data, outpatient dosing, and infection prevention.
Myeloma · New drugs

Explore the full ASH 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in New Orleans. Leave your work email and we’ll be in touch.

Privacy

Download the full ASH 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at CHU de Lille

Tell us what you sell and we’ll find the people at CHU de Lille most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction